The largest database of trusted experimental protocols

4 protocols using lag 3

1

Comprehensive Antibody Panel for Mouse and Human T Cell Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols
For mouse studies, the following antibodies were purchased: from BioLegend: 2B4 (m2B4), BCL-2 (BCL/10C4), CD101 (Moushi101), CD11c (N418), CD127 (A7R34), CD19 (6D5), CD25 (PC61.5), CD3 (145–2C11), CD38 (90), CD39 (Duha59), CD40 (3/23), CD44 (IM7), CD62L (MEL-14), CD69 (H1.2F3), CD70 (FR70), CD80 (16–10A1), CD86 (GL-1), CD90.1 (OX-7 and HIS51), CD90.2 (30-H12 and 53–2.1), CXCR5 (L138D7), Eomes (Dan11mag), GZMB (GB11), IFNγ (XMG1.2), IL-2 (JES6–5H4), KLRG1 (2F1), LAG-3 (C9B7W), MHC I-A/I-E (M5/114.15.2), PD-1 (RMP1–30), T-bet (4B10), TIM-3 (RMT3–23), TNF (MP6-XT22), and 7-amino-actinomycin (7-AAD); from BD Biosciences: annexin V, CD95 (Jo2), Ki67 (B56), Vb7 (TR310); BCL-xL (H-5; Santa Cruz Biotechnology); BIM (C34C5; Cell Signaling Technology), CD8 (53–6.7; eBioscience), CTLA-4 (UC10–410-11; Tonbo Biosciences), TCF-1 (C63D9; Cell Signaling Technology), TIGIT (GIGD7; eBioscience).
For human studies, the following antibodies were purchased: CD39 (A1; BioLegend), CD45RA (HI100; BioLegend), CD45RO (UCHL1; BioLegend), CD8 (RPA-T8; BioLegend), LAG-3 (17B4; Enzo Life Sciences), PD-1 (EH12.1; BD Biosciences) and TIM-3 (F38–2E2; BioLegend).
For flow cytometric detection and analysis of mouse and human TOX, anti-human/mouse TOX antibody clone REA473 was used (Miltenyi Biotec); antibody clone REA293 was used as TOX isotype (Miltenyi Biotec).
+ Open protocol
+ Expand
2

Comprehensive Antibody Panel for Mouse and Human T Cell Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols
For mouse studies, the following antibodies were purchased: from BioLegend: 2B4 (m2B4), BCL-2 (BCL/10C4), CD101 (Moushi101), CD11c (N418), CD127 (A7R34), CD19 (6D5), CD25 (PC61.5), CD3 (145–2C11), CD38 (90), CD39 (Duha59), CD40 (3/23), CD44 (IM7), CD62L (MEL-14), CD69 (H1.2F3), CD70 (FR70), CD80 (16–10A1), CD86 (GL-1), CD90.1 (OX-7 and HIS51), CD90.2 (30-H12 and 53–2.1), CXCR5 (L138D7), Eomes (Dan11mag), GZMB (GB11), IFNγ (XMG1.2), IL-2 (JES6–5H4), KLRG1 (2F1), LAG-3 (C9B7W), MHC I-A/I-E (M5/114.15.2), PD-1 (RMP1–30), T-bet (4B10), TIM-3 (RMT3–23), TNF (MP6-XT22), and 7-amino-actinomycin (7-AAD); from BD Biosciences: annexin V, CD95 (Jo2), Ki67 (B56), Vb7 (TR310); BCL-xL (H-5; Santa Cruz Biotechnology); BIM (C34C5; Cell Signaling Technology), CD8 (53–6.7; eBioscience), CTLA-4 (UC10–410-11; Tonbo Biosciences), TCF-1 (C63D9; Cell Signaling Technology), TIGIT (GIGD7; eBioscience).
For human studies, the following antibodies were purchased: CD39 (A1; BioLegend), CD45RA (HI100; BioLegend), CD45RO (UCHL1; BioLegend), CD8 (RPA-T8; BioLegend), LAG-3 (17B4; Enzo Life Sciences), PD-1 (EH12.1; BD Biosciences) and TIM-3 (F38–2E2; BioLegend).
For flow cytometric detection and analysis of mouse and human TOX, anti-human/mouse TOX antibody clone REA473 was used (Miltenyi Biotec); antibody clone REA293 was used as TOX isotype (Miltenyi Biotec).
+ Open protocol
+ Expand
3

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
GICs and PBMCs were stained for CD3-PE-Cy5.5 (eBioscience), CD4-BV711, CD8-PerCP, CD25-BV605, CD45RA-BV570, CCR7-BV650, CD39-BV421, PD-1-APC-Cy, BTLA-PE, Tim-3-PE-Cy7 (all Biolegend), LAG3 (Enzo Life Sciences, Lörrach, Germany), CTLA4-PE-CF594 (BD) and Live/dead-Aqua dye (Life technologies, Carlsbad, CA) or with isotype controls. Cells were fixed and permeabilized, followed by ICS using Foxp3-FITC (eBioscience) and Ki67-Alexa Fluor 700 (BD) and measured on an LSR Fortessa (BD).
+ Open protocol
+ Expand
4

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cellular composition of leukapheresis samples was determined by flow cytometry using the following antibodies (20 min at 4°C): CD3 (BD), CD19 (BioLegend), and CD56 (BioLegend).
Expression of exhaustion markers was determined by flow cytometry using the following antibodies (20 min at 4°C): CD3 (BD), RQR8 (Qbend10 antibody; R&D), CD8 (BioLegend), LAG3 (Enzo Life Sciences), PD1 (BioLegend), and TIM3 (BioLegend).
All samples were counterstained with 7AAD (BioLegend) to exclude dead cells.
BD Celesta was used for cell acquisition, and data were analyzed using FlowJo V10 (Treestar). Representative plots showing the gating strategy are shown in Supplementary Figure 6A.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!